MXPA02011625A
(es)
*
|
2000-05-26 |
2003-03-27 |
Schering Corp |
Antagonistas receptores de adenosina a2a.
|
GB0100624D0
(en)
*
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
AU2002324846B2
(en)
|
2001-08-31 |
2007-05-10 |
Childrens Hospital Medical Center |
Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain
|
WO2003028732A1
(fr)
*
|
2001-09-28 |
2003-04-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Antagoniste de recepteur
|
HUP0401777A3
(en)
*
|
2001-10-15 |
2008-06-30 |
Schering Corp |
3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
|
EP1453836B1
(en)
|
2001-11-30 |
2007-03-28 |
Schering Corporation |
BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
|
DE60234951D1
(de)
|
2001-11-30 |
2010-02-11 |
Schering Corp |
Adenosin a2a rezeptor antagonisten
|
AR038366A1
(es)
|
2001-11-30 |
2005-01-12 |
Schering Corp |
Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
|
ES2326270T3
(es)
|
2003-04-23 |
2009-10-06 |
Schering Corporation |
Antagonistas del receptor de la adenosina a2a 2-alquinil- y 2-alquenil-pirazolo-(4,3-e)-1,2,4-triazolo-(1,5-c)-pirimidina.
|
ES2342082T3
(es)
|
2004-04-21 |
2010-07-01 |
Schering Corporation |
Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.
|
CN103467471A
(zh)
|
2005-06-06 |
2013-12-25 |
武田药品工业株式会社 |
有机化合物
|
CN101312978A
(zh)
|
2005-09-19 |
2008-11-26 |
先灵公司 |
作为腺苷A2a受体拮抗剂的2-杂芳基-吡唑并-[4,3-e]-1,2,4-三唑并-[1,5-c]-嘧啶
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
WO2007143705A2
(en)
|
2006-06-06 |
2007-12-13 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ES2411604T3
(es)
|
2006-11-13 |
2013-07-05 |
Intra-Cellular Therapies, Inc. |
Compuestos orgánicos
|
US9006258B2
(en)
|
2006-12-05 |
2015-04-14 |
Intra-Cellular Therapies, Inc. |
Method of treating female sexual dysfunction with a PDE1 inhibitor
|
US7691869B2
(en)
|
2007-03-30 |
2010-04-06 |
King Pharmaceuticals Research And Development, Inc. |
Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
|
CN101969774A
(zh)
|
2007-12-06 |
2011-02-09 |
细胞内治疗公司 |
有机化合物
|
CA2845454C
(en)
|
2007-12-06 |
2017-02-07 |
Takeda Pharmaceutical Company Limited |
Organic compounds useful as inhibitors of phosphodiesterase 1
|
AU2009222047A1
(en)
|
2008-03-04 |
2009-09-11 |
Schering Corporation |
1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
|
US20110190324A1
(en)
*
|
2008-07-16 |
2011-08-04 |
Edward Leung |
Methods of treating atherosclerosis
|
CN102238872A
(zh)
|
2008-12-06 |
2011-11-09 |
细胞内治疗公司 |
有机化合物
|
PE20110944A1
(es)
|
2008-12-06 |
2012-01-25 |
Intra Cellular Therapies Inc |
DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
|
JP5813511B2
(ja)
|
2008-12-06 |
2015-11-17 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
EA201170770A1
(ru)
|
2008-12-06 |
2012-02-28 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
EA201170771A1
(ru)
|
2008-12-06 |
2012-01-30 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
AU2009322899A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP2400970A4
(en)
|
2009-02-25 |
2012-07-18 |
Intra Cellular Therapies Inc |
PDE-1-HEMMER FOR EYE DRESSING
|
US9468637B2
(en)
|
2009-05-13 |
2016-10-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JP6166534B2
(ja)
|
2009-08-05 |
2017-07-19 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規調節タンパク質および阻害剤
|
EP2576551A4
(en)
|
2010-05-31 |
2014-04-16 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
US9434730B2
(en)
|
2010-05-31 |
2016-09-06 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
US9371327B2
(en)
|
2010-05-31 |
2016-06-21 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
EP2717877B1
(en)
|
2011-06-10 |
2017-11-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
WO2014101120A1
(en)
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
EP2956141A4
(en)
|
2013-02-17 |
2016-10-26 |
Intra Cellular Therapies Inc |
NEW USES
|
EP2970279B1
(en)
|
2013-03-15 |
2020-09-16 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ES2717688T3
(es)
|
2013-03-15 |
2019-06-24 |
Intra Cellular Therapies Inc |
Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
|
JP6696904B2
(ja)
|
2014-01-08 |
2020-05-20 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
製剤および医薬組成物
|
US9884872B2
(en)
|
2014-06-20 |
2018-02-06 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
ES2745819T3
(es)
|
2014-08-07 |
2020-03-03 |
Intra Cellular Therapies Inc |
Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
|
BR112017005533B1
(pt)
|
2014-09-17 |
2023-10-10 |
Intra-Cellular Therapies, Inc |
Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
|
KR20170083136A
(ko)
|
2014-11-18 |
2017-07-17 |
머크 샤프 앤드 돔 코포레이션 |
A2a 길항제 특성을 갖는 아미노피라진 화합물
|
KR102562576B1
(ko)
|
2014-12-06 |
2023-08-01 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
KR102557603B1
(ko)
|
2014-12-06 |
2023-07-19 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
EP3253390B1
(en)
|
2015-02-06 |
2022-04-13 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as a2a antagonist
|
WO2016200717A1
(en)
|
2015-06-11 |
2016-12-15 |
Merck Sharp & Dohme Corp. |
Aminopyrazine compounds with a2a antagonist properties
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
EP3436083A4
(en)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
NOVEL COMPOSITIONS AND METHOD
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
WO2019118313A1
(en)
|
2017-12-13 |
2019-06-20 |
Merck Sharp & Dohme Corp. |
Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
|
EP3746081A4
(en)
|
2018-01-31 |
2021-10-27 |
Intra-Cellular Therapies, Inc. |
INNOVATIVE USES
|
EP4025202A4
(en)
|
2019-09-03 |
2023-08-02 |
Intra-Cellular Therapies, Inc. |
NOVEL CONNECTIONS
|
CN111072676B
(zh)
*
|
2019-12-12 |
2021-07-16 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|